WHO ICTRP trial
Does recombinant human growth hormone treatment improve AID pregnancy outcomes…
ChiCTR2300068007 · Chinese Clinical Trial Registry (ChiCTR) · Not Recruiting
Key facts
| Trial ID | ChiCTR2300068007 |
|---|---|
| Public title | Does recombinant human growth hormone treatment improve AID pregnancy outcomes among patients with adavanced maternal age and poor prognosis: A prospective randomized controlled study |
| Scientific title | Does recombinant human growth hormone treatment improve AID pregnancy outcomes among patients with adavanced maternal age and poor prognosis: A prospective randomized controlled study |
| Primary sponsor | Guangdong Province Fertility Hospital |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Not Recruiting |
| Study type | Interventional study |
| Phase | 0 |
| Countries | China |
| Conditions | patients with adavanced maternal age and poor prognosis |
| Interventions | Control:standard AID;Growth Hormone Treatment:standard AID with growth hormone treatment for 6 weeks |
| Registration date | Feb 2, 2023 |
| Target size | Control:200;Growth Hormone Treatment:200 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: